Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study

BACKGROUND: In the phase 3 SELECT study, lenvatinib significantly improved prognostic outcomes vs. placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, toxicity of lenvatinib is sometimes considerable and requires frequent dose interruptions and modificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Chihiro, Enokida, Tomohiro, Ueda, Yuri, Suzuki, Shinya, Fujisawa, Takao, Ito, Kazue, Okano, Susumu, Tahara, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598871/
https://www.ncbi.nlm.nih.gov/pubmed/37886165
http://dx.doi.org/10.3389/fonc.2023.1139659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598871/
https://www.ncbi.nlm.nih.gov/pubmed/37886165
http://dx.doi.org/10.3389/fonc.2023.1139659

Ejemplares similares